Clinical Trials
26 trialsTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Clinical Genetics Branch Eligibility Screening Survey
National Institutes of Health Clinical Center (CC)
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
National Institutes of Health Clinical Center (CC)
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
Retinoblastoma Biomarker Study
National Institutes of Health Clinical Center (CC)
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
National Institutes of Health Clinical Center (CC)
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
National Institutes of Health Clinical Center (CC)
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
National Institutes of Health Clinical Center (CC)
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
National Institutes of Health Clinical Center (CC)
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
National Cancer Institute (NCI)
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
National Institutes of Health Clinical Center (CC)